Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Updated Trends in Cancer in Japan: Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence J Epidemiol 31 426-450

[3] Siegel RL(2003)Prospective study of peritoneal recurrence after curative surgery for gastric cancer Br J Surg 90 1113-167

[4] Laversanne M(1992)Neoadjuvant chemotherapy for gastric cancer: Indication and trial setting (in Japanese) Shokakigeka. 15 159-502

[5] Soerjomataram I(2021)Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial Gastric Cancer 24 492-823

[6] Jemal A(2013)A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma Cancer Chemother Pharmacol 72 815-304

[7] Katanoda K(2019)Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial J Clin Oncol. 37 1296-247

[8] Hori M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-655

[9] Saito E(1982)Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649-1708

[10] Shibata A(2016)Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Lancet Oncol 17 1697-2913

[1] Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries CA Cancer J Clin 71 209-249

[2] Ferlay J(2021)Updated Trends in Cancer in Japan: Incidence in 1985-2015 and Mortality in 1958-2018-A Sign of Decrease in Cancer Incidence J Epidemiol 31 426-450

[3] Siegel RL(2003)Prospective study of peritoneal recurrence after curative surgery for gastric cancer Br J Surg 90 1113-167

[4] Laversanne M(1992)Neoadjuvant chemotherapy for gastric cancer: Indication and trial setting (in Japanese) Shokakigeka. 15 159-502

[5] Soerjomataram I(2021)Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial Gastric Cancer 24 492-823

[6] Jemal A(2013)A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma Cancer Chemother Pharmacol 72 815-304

[7] Katanoda K(2019)Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial J Clin Oncol. 37 1296-247

[8] Hori M(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-655

[9] Saito E(1982)Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5 649-1708

[10] Shibata A(2016)Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial Lancet Oncol 17 1697-2913